These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7201593)

  • 1. Progressive supranuclear palsy.
    Login IS
    Neurology; 1982 Aug; 32(8):918-9. PubMed ID: 7201593
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
    Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
    Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methysergide in progressive supranuclear palsy.
    Duncombe AS; Lees AJ
    Neurology; 1985 Jun; 35(6):936-7. PubMed ID: 4000498
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of evidence that the central serotoninergic system plays a role in the activation of prolactin secretion following inhibition of dopamine synthesis or blockade of dopamine receptors in the male rat.
    Krulich L; Coppings RJ; Giachetti A; McCann SM; Mayfield MA
    Neuroendocrinology; 1980; 30(3):133-8. PubMed ID: 6445044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brainstem auditory evoked responses in progressive supranuclear palsy.
    Tolosa ES; Zeese JA
    Ann Neurol; 1979 Oct; 6(4):369. PubMed ID: 554529
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive supranuclear palsy 1979: an overview.
    Brusa A; Mancardi GL; Bugiani O
    Ital J Neurol Sci; 1980 Oct; 1(4):205-22. PubMed ID: 7338456
    [No Abstract]   [Full Text] [Related]  

  • 7. Sleep disturbances in progressive supranuclear palsy.
    Gross RA; Spehlmann R; Daniels JC
    Electroencephalogr Clin Neurophysiol; 1978 Jul; 45(1):16-25. PubMed ID: 78818
    [No Abstract]   [Full Text] [Related]  

  • 8. [Progressive supranuclear palsy: a case report and etiological study of eye movement disturbance].
    Kawamura Y; Shibazaki H; Shida K; Goto I; Kuroiwa Y
    Rinsho Shinkeigaku; 1975 Aug; 15(8):535-40. PubMed ID: 1237380
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of progressive supranuclear palsy--neurotological findings and etiology.
    Umeda Y; Sakata E
    J Otolaryngol; 1978 Oct; 7(5):409-14. PubMed ID: 739573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
    Kish SJ; Chang LJ; Mirchandani L; Shannak K; Hornykiewicz O
    Ann Neurol; 1985 Nov; 18(5):530-6. PubMed ID: 2416269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography.
    Baron JC; Maziere B; Loc'h C; Sgouropoulos P; Bonnet AM; Agid Y
    Lancet; 1985 May; 1(8438):1163-4. PubMed ID: 2860368
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy.
    Baron JC; Mazière B; Loc'h C; Cambon H; Sgouropoulos P; Bonnet AM; Agid Y
    J Cereb Blood Flow Metab; 1986 Apr; 6(2):131-6. PubMed ID: 3485639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
    Jackson JA; Jankovic J; Ford J
    Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive supranuclear palsy: the relationship between ocular motor dysfunction and psychological test performance.
    Fisk JD; Goodale MA; Burkhart G; Barnett HJ
    Neurology; 1982 Jul; 32(7):698-705. PubMed ID: 7201107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive supranuclear palsy: postmortem chemical analysis.
    Young AB
    Ann Neurol; 1985 Nov; 18(5):521-2. PubMed ID: 2866753
    [No Abstract]   [Full Text] [Related]  

  • 16. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.
    Rafal RD; Grimm RJ
    Neurology; 1981 Dec; 31(12):1507-18. PubMed ID: 7198201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of progressive supranuclear palsy with tricyclic antidepressants.
    Newman GC
    Neurology; 1985 Aug; 35(8):1189-93. PubMed ID: 3895032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of progressive supranuclear paralysis. Effect of methysergide and bromocriptine on various psychoneurologic and motor functions].
    Giménez-Roldán S; de Andrés C; Salinero E
    Rev Clin Esp; 1979 Apr; 153(1):21-7. PubMed ID: 461893
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.
    Neophytides A; Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Bock J; Walker R
    J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):261-3. PubMed ID: 7086448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blink rates and disorders of movement.
    Karson CN; Burns RS; LeWitt PA; Foster NL; Newman RP
    Neurology; 1984 May; 34(5):677-8. PubMed ID: 6231489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.